Navigation Links
Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints

sleep habits.

Study Results

Primary Outcome Measure (change in mean SCORAD score measured at Day 28 compared to Baseline).

Daily (twice) applications of both Cutivate(R) Cream and EpiCeram(TM) produced significant reductions in SCORAD scores at Day 28 compared to baseline values. Daily (twice) applications of EpiCeram(TM) produced statistically significant improvement of atopic dermatitis after 28 days with a reduction in SCORAD scores of 56.41% from baseline. Daily (twice) applications of the comparator product, Cutivate(R) cream, also produced statistically significant improvement of atopic dermatitis after 28 days with a reduction in SCORAD scores of 68.77%. Statistical comparison of the treatment effects (SCORAD scores) showed no statistically significant difference between treatment effects after 28 days of treatment.

Secondary Outcome Measures.

A. Percentage of subjects reaching clear or almost clear on IGA at Day 28

Assessment of the disease progression showed significant improvements in the IGA scores over time for both EpiCeram(TM) and Cutivate(R) cream with 61.1% of the EpiCeram(TM) patients assessed as clear or almost clear after 28 days of treatment and 76.2% of the Cutivate(R) cream patients being assessed as clear or almost clear at Day 28. Comparison of the disease progression results for both treatments showed no statistically significant difference between EpiCeram(TM) and Cutivate(R) cream after 28 days of treatment.

B. Assessment of Pruritus.

Patient reported assessments of pruritus also showed significant improvement from baseline after 28 days of treatment for both EpiCeram(TM) (3.54 change from baseline) and Cutivate(R) cream (3.75 change from baseline). No statistically significant differences were found between treatments after 28 days of treatment.

C. Assessment of Sleep Habits.

Patient reported assessments of sleep habits also showed significant improvement from b
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces New Publication of Scientific Research on Ceragenin Technology
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:7/30/2015)... 30, 2015 IRIDEX Corporation (NASDAQ: IRIX ... quarter 2015 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, August 6, 2015 ... business developments. Interested parties may access the ...
(Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of #MedicareMonday ... remind you about some of our Medicare resources and continue highlighting the success of ... Check out our latest infographics and videos here: ... ... ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... ResMed Inc. (NYSE: RMD ) announced today that it will be ... ... 4, 2010 ; Jefferies Global Life Sciences Conference at the Grand Hyatt in ... Conference at the Four Seasons in Chicago on June 16, 2010 ; ...
... April 27 AstraZeneca LP and AstraZeneca ... resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug ... by the Food and Drug Administration (FDA), the Departments ... Fraud Enforcement Action Team (HEAT) announced today.  Such unapproved ...
Cached Medicine Technology:ResMed Inc. to Present at Upcoming Conferences 2Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 2Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 3Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 4Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 5Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing 6
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair ... that they are the latest recipients of the Center of Clinical Excellence for ... the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration ...
(Date:7/31/2015)... ... ... is a reputable source of authentic USA vs. Australia tickets at Ford Field ... Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World Cup ... was awarded the Golden Ball as the best player of the 2015 Women's World Cup. ...
(Date:7/31/2015)... Miami, FL (PRWEB) , ... July 31, 2015 , ... ... die everyday as a direct result of heroin use and eventual overdoses. Thricefold deaths ... is struggling to get a handle on the Sarasota heroin epidemic, which was spurred ...
(Date:7/31/2015)... ... ... Physical therapy for knee osteoarthritis is an important part of knee ... patient from doing what they want or need to do. The patient may have trouble ... The patient's exercise regime may be limited by the pain in their knee. When a ...
(Date:7/31/2015)... ... July 31, 2015 , ... A family-run business in ... from ingredients sourced all over the world, then manufactured into specific formulations in ... developed the highest-quality oils in the industry, which we are bringing to consumers ...
Breaking Medicine News(10 mins):Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Living Pure Essential Oils takes Therepeutic Essential Oil Market by Storm 2
... has been made by McMaster researchers about Fragile X ... one in 4,000 males and one in 6,000 females. ... associated with mental impairment. The affected gene (FMR1) leads ... the fragile X mental retardation protein (FMRP). , ...
... PHILADELPHIA Scientists and clinicians from around the ... at the American Association for Cancer Researchs second ... Development. The conference is subtitled Maximizing Opportunities for ... diagnostics to provide new strategies for tailoring therapies ...
... LOMA LINDA, Calif., Sept. 10 Loma ... Day Adventist institution located,in Southern California, has ... physician referrals and outbound reminder calls for ... seeking physician referrals for breast care, psychology, ...
... Harvard Medical School,researchers have honored BlueCross BlueShield of ... providers to obtain member pre-,certifications in seconds over ... less costly. Researchers from the medical school,s ... tool as one of seven national,BlueWorks(R) winners in ...
... ABBOTT PARK, Ill., Sept. 10 Abbott (NYSE:,ABT) ... named to the Dow Jones,Sustainability World Index and ... third consecutive year. This selection recognizes Abbott,s,continued leadership ... is a critical part of our approach to ...
... ATLANTA, Sept. 10 Coalition America, Inc. (CAI),announces ... strategy officer who,will lead the deployment efforts of ... continuous new product development,initiatives. Brown comes to ... the,healthcare industry having held management roles in various ...
Cached Medicine News:Health News:Stem cell research produces a key discovery for Fragile X Syndrome 2Health News:Scientists, physicians present latest findings in 'personalized' cancer treatment and prevention 2Health News:Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Women's Services Programs and Departments 2Health News:Harvard Researchers Select S.C. BlueCross for National Honor 2Health News:Harvard Researchers Select S.C. BlueCross for National Honor 3Health News:Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance 2Health News:Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer 2
The Multiple Perfusion set provides simultaneous perfusion of the aortic root and up to three or more vein grafts. The set features an inlet port with female luer and clamp attached to an adapter whi...
The Aortic Root Cannulae With Vent Line are flanged, with radiopaque tips; two side holes in tip....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
... Medtronic Select CAP® cannulae provides a ... pressure readings. An innovative combination of ... monitoring line, the Select CAP® can ... central arterial pressure readings on which ...
Medicine Products: